[go: up one dir, main page]

WO2013053072A1 - Composition permettant d'améliorer la fonction du tube digestif en aidant à réduire les taux de sucre et de lipides dans le sang - Google Patents

Composition permettant d'améliorer la fonction du tube digestif en aidant à réduire les taux de sucre et de lipides dans le sang Download PDF

Info

Publication number
WO2013053072A1
WO2013053072A1 PCT/CN2011/001687 CN2011001687W WO2013053072A1 WO 2013053072 A1 WO2013053072 A1 WO 2013053072A1 CN 2011001687 W CN2011001687 W CN 2011001687W WO 2013053072 A1 WO2013053072 A1 WO 2013053072A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
composition
oligopeptide
blood sugar
reductions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2011/001687
Other languages
English (en)
Chinese (zh)
Inventor
黄代勇
钱金宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/CN2011/001687 priority Critical patent/WO2013053072A1/fr
Publication of WO2013053072A1 publication Critical patent/WO2013053072A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/28—Substances of animal origin, e.g. gelatin or collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof

Definitions

  • composition for improving blood sugar and blood lipid based on improvement of gastrointestinal function Composition for improving blood sugar and blood lipid based on improvement of gastrointestinal function
  • the invention belongs to the technical field of functional foods, and particularly relates to a composition for improving blood sugar and blood lipids by improving gastrointestinal function, and is a combination capable of lowering blood sugar, blood fat and enhancing human immunity on the basis of improving intestinal micro-ecological environment. Things. Background technique
  • the above technologies and products have the following disadvantages:
  • the strains in the live bacterial preparation are single, and the flora in the human intestinal tract is a complicated system, and the second is that the live bacterial preparation is an industrial manufactured product of laboratory strains, and the application individual The compatibility is very poor.
  • the oligofructose and xylooligosaccharide used in the current products are low-middle. product. Their proliferation effect on Bifidobacteria and Lactobacillus is only 5 to 10 times, and it is not possible to directly reduce harmful bacteria such as Enterobacter. The application of these products requires a large dosage.
  • the object of the present invention is to provide a composition capable of assisting blood fat reduction composed of oligosaccharides, oligopeptides, grape seed extract and natural astaxanthin, thereby improving human intestinal flora, lowering blood fat and improving human immunity.
  • the technical solution of the present invention is composed of chitosan oligosaccharide, mannose oligosaccharide, protein hydrolysate (oligopeptide), grape seed extract, natural astaxanthin, and the content thereof is percentage by weight: shell is low Chitosan oligosaccharides (COS) 30.0% ⁇ 50.0%, Mannose oligosaccharides (MOS) 10.0%-30.0%, protein hydrolysate (oligopeptide) 5.0% ⁇ 15.0%, grape seed extract 1.0% ⁇ 5.0%, natural astaxanthin (Ataxanthin, ASTA)
  • the method of making the composition into a capsule type is - compounding.
  • the composition components such as mannooligosaccharide, chitosan oligosaccharide, protein hydrolyzate (oligopeptide), grape seed extract (powder), natural astaxanthin in the composition are loaded into a WZL800 gravityless mixer, and well mixed.
  • Granulation is dry.
  • the above mixed composition was transferred to an LGL200 fluidized bed granulation drying (boiling granulation) machine for granulation and drying.
  • the granulated composition is transferred to a ZS400 oscillating sieve, and the 80-120 mesh material is selected for transfer to the next step.
  • the sieved composition is canned in a capsule can.
  • the present invention is prepared by processing chitosan oligosaccharides, mannooligosaccharides, protein hydrolysates (oligopeptides), biologically active calcium, and ganoderma lucidum spore powder in percentage by weight: chitooligosaccharides (Chitosan oligosaccharides, COS ) 30.0% ⁇ 50.0%, Mannose oligosaccharides (MOS) 10.0% ⁇ 30.0%, protein hydrolysate (oligopeptide) 5.0% ⁇ 15.0%, grape seed extract 1.0% ⁇ 5.0% Natural astaxanthin (ASTA) is 0.01% ⁇ 0.02%.
  • Astaxanthin 0.01%, 0.035mg
  • composition such as mannooligosaccharide, chitosan oligosaccharide, protein hydrolyzate (oligopeptide), ganoderma lucidum spore powder and bioactive calcium were placed in a WZL800 gravity-free mixer, and mixed.
  • Granulation is dry.
  • the above mixed composition was transferred to a LGL200 fluidized bed granulation drying (boiling granulation) machine for granulation and drying.
  • Astaxanthin 0.01%, 0.035mg
  • the human functional test showed that the composition could significantly increase the number of bifidobacteria and lactobacilli in the human body, and the difference was extremely significant (P ⁇ 0.01).
  • the number of Bacteroides increased significantly, and the difference was significant (P ⁇ 0.05), the number of Enterobacteriaceae was significantly reduced, the difference was extremely significant (P ⁇ 0.01), and the number of Enterococcus and Clostridium perfringens did not change significantly.
  • HDL- C If reduced: May have coronary heart disease, atherosclerosis.
  • the invention Compared with the existing products, the invention has the effects of regulating intestinal flora, assisting blood fat reduction, improving immunity, and comprehensively enhancing vitality.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition préparée à partir de chitooligosaccharides, d'un oligosaccharide de mannane, d'un oligopeptide, de pépin de raisin, d'une astaxanthine de crevette naturelle de proportions données, le pourcentage en poids des composants étant : 30,0 à 50,0 % de chitooligosaccharide, 10,0 à 30,0 % de l'oligosaccharide de mannane, 5,0 à 15,0 % d'un hydrolysat de protéine (l'oligopeptide), 1,0 à 5,0 % d'un extrait de pépin de raisin, et 0,01 à 0,02 % de l'astaxanthine de crevette naturelle. La composition favorise la croissance d'une flore intestinale bénéfique, réduisant les taux de sucre et de lipides dans le sang, et améliorant l'immunité humaine.
PCT/CN2011/001687 2011-10-10 2011-10-10 Composition permettant d'améliorer la fonction du tube digestif en aidant à réduire les taux de sucre et de lipides dans le sang Ceased WO2013053072A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/001687 WO2013053072A1 (fr) 2011-10-10 2011-10-10 Composition permettant d'améliorer la fonction du tube digestif en aidant à réduire les taux de sucre et de lipides dans le sang

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/001687 WO2013053072A1 (fr) 2011-10-10 2011-10-10 Composition permettant d'améliorer la fonction du tube digestif en aidant à réduire les taux de sucre et de lipides dans le sang

Publications (1)

Publication Number Publication Date
WO2013053072A1 true WO2013053072A1 (fr) 2013-04-18

Family

ID=48081321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/001687 Ceased WO2013053072A1 (fr) 2011-10-10 2011-10-10 Composition permettant d'améliorer la fonction du tube digestif en aidant à réduire les taux de sucre et de lipides dans le sang

Country Status (1)

Country Link
WO (1) WO2013053072A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104905112A (zh) * 2015-06-19 2015-09-16 青岛浩大海洋保健食品有限公司 一种具有延缓衰老功效的海洋保健胶囊
EP3040069A4 (fr) * 2013-06-27 2017-04-12 The Doshisha Composition améliorant la flore intestinale contenant de l'asthaxanthine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101010090A (zh) * 2004-08-13 2007-08-01 小高勇 糖尿病预防·改善剂以及糖尿病的预防·改善用功能性食品
CN101185511A (zh) * 2006-11-17 2008-05-28 广州伯凯生物技术有限公司 具有肠胃微生态调节作用的保健方便面食品的制作方法
CN101224006A (zh) * 2008-02-04 2008-07-23 马宏达 一种具有抗氧化功效的保健胶囊及其制备方法
CN101715913A (zh) * 2008-12-02 2010-06-02 天津天狮生物发展有限公司 一种活力康胶囊及其生产制作工艺

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101010090A (zh) * 2004-08-13 2007-08-01 小高勇 糖尿病预防·改善剂以及糖尿病的预防·改善用功能性食品
CN101185511A (zh) * 2006-11-17 2008-05-28 广州伯凯生物技术有限公司 具有肠胃微生态调节作用的保健方便面食品的制作方法
CN101224006A (zh) * 2008-02-04 2008-07-23 马宏达 一种具有抗氧化功效的保健胶囊及其制备方法
CN101715913A (zh) * 2008-12-02 2010-06-02 天津天狮生物发展有限公司 一种活力康胶囊及其生产制作工艺

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3040069A4 (fr) * 2013-06-27 2017-04-12 The Doshisha Composition améliorant la flore intestinale contenant de l'asthaxanthine
CN104905112A (zh) * 2015-06-19 2015-09-16 青岛浩大海洋保健食品有限公司 一种具有延缓衰老功效的海洋保健胶囊

Similar Documents

Publication Publication Date Title
Shen et al. Effects of oat β-glucan and barley β-glucan on fecal characteristics, intestinal microflora, and intestinal bacterial metabolites in rats
Tester et al. Glucomannans and nutrition
Wichers Immunomodulation by food: promising concept for mitigating allergic disease?
EP2643005B1 (fr) Composition comportant des protéines hydrolysées et des oligosaccharides pour le traitement des maladies de la peau
CN107115364B (zh) 一种复合益生菌及其制备方法
CN104206946A (zh) 用于促进肠微生物群平衡和健康的营养组合物
CN103431134A (zh) 一种含益生元的压片糖果及其制备方法
CN101317666A (zh) 高效复合膳食纤维素及其制备方法
TW201242518A (en) Oligosaccharide mixture and food product comprising this mixture, especially infant formula
CN108697721A (zh) 用于预防婴儿或幼儿日后的肥胖或相关并存病的包含2FL和LNnT的组合物
CN102342415B (zh) 一种改善胃肠道功能辅助降低血糖和血脂的组合物
WO2015146916A1 (fr) Nouvelle souche de lactobacillus paracasei
Kumari et al. Synergistic role of prebiotics and probiotics in gut microbiome health: Mechanisms and clinical applications
CN108208843A (zh) 一种调节肠道菌群的保健组合物及其用途
CN105744939A (zh) 用于治疗或预防流行性感冒感染的含有2-岩藻糖基化低聚糖的婴儿配方食品
CN111000246A (zh) 一种辅助降甘油三酯的益生菌膳食纤维组合物及其应用、保健品
Rawat et al. Recent developments in the production of prebiotic fructooligosaccharides using fungal fructosyltransferases
Jain et al. Amorphophallus konjac: traditional uses, bioactive potential, and emerging health applications
WO2013053072A1 (fr) Composition permettant d'améliorer la fonction du tube digestif en aidant à réduire les taux de sucre et de lipides dans le sang
CN114146120B (zh) 一种预防及治疗萎缩性胃炎的组合物微胶囊及其制备方法
CN105166765A (zh) 一种甘露寡糖合生元肠溶微胶囊的制备方法
de la Rosa et al. Fructooligosaccharides as prebiotics, their metabolism, and health benefits
CN107950864A (zh) 一种合生元谷蔬代餐粉及其制备方法和应用
US20250170080A1 (en) Compositions comprising butyric acid and gluconic acid for the treatment of disorders and syndromes associated with intestinal barrier dysfunctions and dysbiosis
Sharma et al. Pre-and probiotics: Using functional foods in the fight against microbial resistance to antibiotics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11874100

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 08/08/2014).

122 Ep: pct application non-entry in european phase

Ref document number: 11874100

Country of ref document: EP

Kind code of ref document: A1